Faeth Therapeutics is a clinical-stage oncology company listed on Nasdaq, recently securing $200M in funding. With a strong scientific foundation and a founding team that includes the discoverer of a key target pathway, the company is advancing its PIKTOR program, a multi-node PI3K/AKT/mTOR inhibitor, towards significant milestones. Faeth Therapeutics fosters a small, focused team environment where each member has a direct impact, united by a commitment to care deeply, create boldly, and continuously learn.